Clinical Trials · NCT00258193

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

CompletedPhase 2Linaclotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Ironwood Pharmaceuticals, Inc.
Enrollment
36
Start date
Jan 2006
Locations
1 site, United States
Primary endpoint
(Safety) AEs to be collected beginning with patient's first administration of study medication through final study visit
View Linaclotide compound reference